Stage managing bipolar disorder

Bipolar Disorders

Volumn 16, Issue 5, 2014, Pages 471-477

  Berk, Michael ^a,b,c,d   Berk, Lesley ^a,c   Dodd, Seetal ^a,b   Cotton, Sue ^c   Macneil, Craig ^c   Daglas, Rothanthi ^b,c   Conus, Philippe ^e   Bechdolf, Andreas ^c,f   Moylan, Steven ^a   Malhi, Gin S ^g,h  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF COLOGNE   (Germany)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bipolar disorder; Clinical staging; Depression; Early intervention; Mania; Neuroprogression; Treatment

Indexed keywords

BIOLOGICAL MARKER;

BIPOLAR DISORDER; COGNITION; EARLY INTERVENTION; HUMAN; NEUROIMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; DISEASE COURSE; DISEASE MANAGEMENT; PATHOPHYSIOLOGY; PROGNOSIS;

BIPOLAR DISORDER; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; PROGNOSIS;

EID: 84905221086     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12099     Document Type: Review

References (48)

1. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40: 616-622.
2. Berk M, Conus P, Lucas N et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007; 9: 671-678.
3. Berk M, Jacka F. Preventive strategies in depression: gathering evidence for risk factors and potential interventions. Br J Psychiatry 2012; 201: 339-341.
4. Berk M, Conus P, Kapczinski F et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust 2010; 193: S36-S40.
5. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007; 100: 279-281.
6. Dodd S, Berk M. Predictors of antidepressant response: a selective review. Int J Psychiatry Clin Pract 2004; 8: 91-100.
7. McGorry PD, Nelson B, Goldstone S, Yung AR. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry 2010; 55: 486-497.
8. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993; 87: 225-230.
9. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009; 9: 957-966.
10. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007; 31: 858-873.
11. Post RM, Rubinow DR, Ballenger JC. Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry 1986; 149: 191-201.
12. le Grange D, Loeb KL, Van Orman S, Jellar CC. Bulimia nervosa in adolescents: a disorder in evolution? Arch Pediatr Adolesc Med 2004; 158: 478-482.
13. Fava GA, Rafanelli C, Tossani E, Grandi S. Agoraphobia is a disease: a tribute to Sir Martin Roth. Psychother Psychosom 2008; 77: 133-138.
14. Gelenberg AJ, Kane JM, Keller MB et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489-1493.
15. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264-1266.
16. Franchini L, Zanardi R, Smeraldi E, Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci 1999; 249: 227-230.
17. Berk M, Brnabic A, Dodd S et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 2011; 13: 87-98.
18. Magalhães PV, Dodd S, Nierenberg AA, Berk M. Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Aust N Z J Psychiatry 2012; 46: 1058-1067.
19. Lam DH, Burbeck R, Wright K, Pilling S. Psychological therapies in bipolar disorder: the effect of illness history on relapse prevention - a systematic review. Bipolar Disord 2009; 11: 474-482.
20. Scott J, Paykel E, Morriss R et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry 2006; 188: 313-320.
21. Reinares M, Colom F, Rosa AR et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord 2010; 123: 81-86.
22. Colom F. Long-term follow up of psychotherapies in bipolar disorder. Bipolar Disord 2008; 10 (Suppl. 1): 20.
23. Macneil CA, Hasty M, Cotton S et al. Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study. Early Interv Psychiatry 2012; 6: 380-388.
24. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
25. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007; 10: 1089-1093.
26. Lisy ME, Jarvis KB, DelBello MP et al. Progressive neurostructural changes in adolescent and adult patients with bipolar disorder. Bipolar Disord 2011; 13: 396-405.
27. López-Jaramillo C, Lopera-Vásquez J, Gallo A et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord 2010; 12: 557-567.
28. Strakowski SM, DelBello MP, Zimmerman ME et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am J Psychiatry 2002; 159: 1841-1847.
29. Lyoo IK, Sung YH, Dager SR et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 2006; 8: 65-74.
30. Fornito A, Malhi GS, Lagopoulos J et al. In vivo evidence for early neurodevelopmental anomaly of the anterior cingulate cortex in bipolar disorder. Acta Psychiatr Scand 2007; 116: 467-472.
31. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009; 113: 1-20.
32. El-Badri SM, Ashton CH, Moore PB, Marsh VR, Ferrier IN. Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder. Bipolar Disord 2001; 3: 79-87.
33. Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord 2006; 8: 103-116.
34. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010.
35. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008; 32: 675-692.
36. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008; 29: 346-351.
37. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol 2002; 17: 175-179.
38. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 447-458.
39. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 2009; 34: 263-271.
40. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18: 595-606.
41. Bechdolf A, Nelson B, Cotton SM et al. A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. J Affect Disord 2010; 127: 316-320.
42. Bechdolf A, Ratheesh A, Wood SJ et al. Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder. Curr Pharm Des 2012; 18: 358-375.
43. Leopold K, Ritter P, Correll CU et al. Risk constellations prior to the development of bipolar disorders: rationale of a new risk assessment tool. J Affect Disord 2012; 136: 1000-1010.
44. Berk M, Dodd S, Callaly P et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord 2007; 103: 181-186.
45. Malhi GS, Chengappa KN, Gershon S, Goldberg JF. Hypomania: hype or mania? Bipolar Disord 2010; 12: 758-763.
46. Macneil CA, Hallam K, Conus P, Henry L, Kader L, Berk M. Are we missing opportunities for early intervention in bipolar disorder? Expert Rev Neurother 2012; 12: 5-7.
47. Macneil CA, Hasty MK, Berk M et al. Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. Early Interv Psychiatry 2011; 5: 100-107.
48. Berk L, Jorm AF, Kelly CM, Dodd S, Berk M. Development of guidelines for caregivers of people with bipolar disorder: a Delphi expert consensus study. Bipolar Disord 2011; 13: 556-570.